Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Anal high-grade squamous intraepithelial lesions (precursor), drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Most HSIL never progresses, and no marker yet says which lesions to treat and which to watch.
High-resolution anoscopy is scarce outside specialist centres.
Recurrence after ablation is common and the best retreatment strategy is untested.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Whether screening helps people at high risk who do not have HIV is unproven.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 6 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Progression to anal cancer 173 per 100,000 person-years with treatment against 402 with active monitoring, a 57 percent reduction (95% CI 6 to 80, p 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.